Boyd Wealth Management’s VistaGen Therapeutics VTGN Stock Holding History

Boyd Wealth Management’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-406	Closed	-$1.52K	–	45
2023 Q1	$1.52K	Hold	406	–	–	﹤0.01%	40
2022 Q4	$1.25K	Hold	406	–	–	﹤0.01%	43
2022 Q3	$2K	Buy	+406	New	+$4.02K	﹤0.01%	42

Other funds holding VTGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boyd Wealth Management's VTGN Position: Q2 2023 in Review

Boyd Wealth Management sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 406 shares — an estimated $1.52K sold.

Boyd Wealth Management first reported a position in VTGN in Q3 2022 and held it in 3 quarters. The position peaked at $2K in Q3 2022. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

Boyd Wealth Management reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
Boyd Wealth Management sold 406 VistaGen Therapeutics shares in Q2 2023, an estimated $1.52K.
Boyd Wealth Management first reported a position in VistaGen Therapeutics in Q3 2022 and held it in 3 quarters.
Boyd Wealth Management's VistaGen Therapeutics position peaked at $2K in Q3 2022.
33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Boyd Wealth Management's 13F filing for Q2 2023, filed 20 Jul 2023.